Local Angiotensin II Modulates Ferroptosis and Radiosensitivity in Nasopharyngeal Carcinoma via the HIF-1α-HILPDA Axis

Study Background and Research Question

Nasopharyngeal carcinoma (NPC) is an epithelial malignancy originating from the mucosal lining of the nasopharynx, with a high incidence in East and Southeast Asia. Radiotherapy remains the primary curative approach for NPC due to the tumor's anatomical inaccessibility and initial radiosensitivity. However, up to 20% of patients experience local recurrence or residual disease, attributed primarily to the development of radioresistance. Understanding the molecular mechanisms underlying this radioresistance is essential for improving patient outcomes and guiding the design of more effective radiosensitizing treatments. The renin-angiotensin system (RAS), classically known for its role in cardiovascular regulation, has emerged as a critical modulator within tumor microenvironments. In NPC, local angiotensin II (Ang II)—produced by angiotensinogen (AGT) in hypoxic tumor regions—has been implicated in tumor proliferation and therapy resistance. The reference study (Chen et al., 2025) investigated how local Ang II influences radioresistance in NPC, focusing on its interplay with ferroptosis (a form of regulated cell death) and the HIF-1α-HILPDA signaling axis.

Key Innovation from the Reference Study

A central innovation of this research is the elucidation of a feedback mechanism wherein local Ang II enhances NPC radioresistance by suppressing ferroptosis via the HIF-1α-HILPDA pathway. The study demonstrates that Ang II, concentrated in hypoxic tumor microenvironments, both stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) by activating the MAPK pathway and prevents its degradation through direct AGT binding. This dual regulatory action leads to upregulation of hypoxia-inducible lipid droplet-associated protein (HILPDA), fostering lipid droplet accumulation and inhibiting ferroptosis. The identification of this AGT-HIF-1α-HILPDA axis as a driver of radioresistance is a significant conceptual advance, providing new molecular targets for radiosensitization in NPC.

Methods and Experimental Design Insights

The study leveraged a comprehensive suite of molecular and cellular biology techniques to dissect the role of local Ang II in NPC radioresistance:

• Radioresistant NPC cell lines: HONE1-RR and SUNE1-RR were established to model clinical radioresistance.
• Gene and protein expression: AGT, HIF-1α, HILPDA, and GPX4 levels were quantified using qRT-PCR, western blotting, and ELISA.
• Functional assays: Transmission electron microscopy, ferrous ion detection, and lipid oxidation assays measured radiation-induced ferroptosis.
• Mechanistic interrogation: Bioinformatics, co-immunoprecipitation, and dual-luciferase reporter assays dissected the regulatory relationships among Ang II, AGT, HIF-1α, and HILPDA.
• Radiosensitivity assessment: Colony formation, Cell Counting Kit-8 (CCK8), and nude mouse xenograft models evaluated the impact of pathway modulation on tumor response to radiotherapy.
• Tissue validation: Immunohistochemistry in clinical NPC samples validated the correlation between pathway activation, ferroptosis markers, and clinical outcomes.

This multi-level approach ensured robust mechanistic insight and translational relevance.

Core Findings and Why They Matter

The study uncovered several critical findings:

• Local Ang II is a key driver of radioresistance in NPC, acting through a positive feedback loop with HIF-1α (Chen et al., 2025).
• Ang II enhances HIF-1α stability via MAPK/ERK pathway activation, while AGT directly binds and protects HIF-1α from degradation.
• HIF-1α transcriptionally activates HILPDA, leading to increased lipid droplet accumulation and suppression of ferroptosis—a form of cell death known to sensitize tumor cells to radiation.
• Inhibition of Ang II signaling—particularly when combined with ferroptosis inducers—markedly increases radiosensitivity in NPC models, indicating a synergistic therapeutic benefit.
• Expression levels of AGT, HIF-1α, HILPDA, and GPX4 strongly correlate with ferroptosis intensity, radiosensitivity, and clinical prognosis in NPC.

These results provide a compelling rationale for targeting the AGT-HIF-1α-HILPDA axis in NPC to overcome radioresistance and improve patient outcomes.

Comparison with Existing Internal Articles

The findings from this study align with and extend prior internal reviews. For instance, a related analysis (see internal summary) confirmed that local Ang II suppresses ferroptosis in NPC and highlighted the clinical relevance of combining Ang II blockade with ferroptosis induction. Another synthesis (internal resource) emphasized actionable targets within the HIF-1α-HILPDA pathway for radiosensitization. This reference study distinguishes itself by mapping the dual regulatory mechanism of Ang II—through both ERK pathway activation and AGT-HIF-1α direct interaction—offering a more detailed mechanistic landscape for therapeutic intervention. Furthermore, methodological parallels exist with translational work on ERK1/2 pathway inhibitors in tumor models. For example, selective ERK1/2 inhibition with SCH772984, as described in another internal article (see resource), has been shown to effectively dissect MAPK-dependent resistance mechanisms in preclinical settings, illustrating the utility of targeted pathway modulation in radiosensitization research.

Limitations and Transferability

While the study provides robust preclinical evidence, several limitations should be considered:

• Model specificity: The findings are based on established radioresistant NPC cell lines and xenograft models, which may not fully recapitulate the diversity of clinical NPC cases.
• Pathway complexity: The MAPK/ERK and ferroptosis regulatory networks are highly context-dependent; their modulation may yield variable results across different tumor types or microenvironmental conditions.
• Therapeutic translation: Although Ang II receptor antagonists and ferroptosis inducers show promise in preclinical models, clinical validation in NPC patients will be required to establish efficacy and safety.

Nevertheless, the central role of the AGT-HIF-1α-HILPDA axis in mediating radioresistance is likely to be relevant to a broad range of hypoxic, therapy-resistant tumors.

Protocol Parameters

• Cell line establishment: Radioresistant NPC lines (HONE1-RR, SUNE1-RR) generated via repeated exposure to fractionated ionizing radiation, followed by clonal selection.
• Ferroptosis detection: Lipid peroxidation assessed by C11-BODIPY 581/591 fluorescence; ferrous ion measured with colorimetric iron assays post-irradiation.
• Pathway modulation: Ang II receptor blockade administered at optimized concentrations (per in vitro dose–response curves); ferroptosis inducers (e.g., erastin, RSL3) applied as per established protocols.
• Tumor radiosensitivity: Colony formation assay performed 10–14 days post-irradiation; xenograft models evaluated by tumor volume measurements twice weekly.
• Protein expression analysis: Immunohistochemistry and western blotting for AGT, HIF-1α, HILPDA, and GPX4 using validated antibodies; results normalized to β-actin or GAPDH.

Research Support Resources

To facilitate mechanistic studies of the MAPK/ERK pathway and its role in radioresistance, researchers may incorporate selective ERK1/2 inhibitors such as SCH772984 (SKU A3805) into their experimental workflows. SCH772984, available from APExBIO, is a potent ATP-competitive ERK1/2 inhibitor with nanomolar selectivity, supporting in vitro and in vivo pathway modulation in BRAF, NRAS, and KRAS mutant tumor models. For detailed experimental guidance, consult literature-backed protocols and ensure compatibility with specific cell-based or xenograft assay systems.